High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Actavis has a broad product portfolio and strong pipeline.

Our Research and Development (R&D) strategy for our generic products focuses on the following product development areas:

  • Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines; 

  • Patent challenge products where the company believes either the brand patent is invalid or its product does not infringe; and

  • The development of sustained-release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, inhalation and other drug delivery technologies and the application of these technologies to proprietary drug forms.